Drug Approval | April 20, 2022
BDR Pharmaceuticals launch Furmecil to treat advanced gastric cancer
The launch is yet another first of its kind innovation in India
The launch is yet another first of its kind innovation in India
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Subscribe To Our Newsletter & Stay Updated
